|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG
and Lee JS: Cancer statistics in Korea: Incidence, mortality,
survival and prevalence in 2010. Cancer Res Treat. 45:1–14. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
D'Angelica M, Gonen M, Brennan MF, et al:
Patterns of initial recurrence in completely resected gastric
adenocarcinoma. Ann Surg. 240:808–816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Macdonald JS: Gastric cancer - new
therapeutic options. N Engl J Med. 355:76–77. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wagner AD, Grothe W, Haerting J, et al:
Chemotherapy in advanced gastric cancer: A systematic review and
meta-analysis based on aggregate data. J Clin Oncol. 24:2903–2909.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wagner AD, Unverzagt S, Grothe W, et al:
Chemotherapy for advanced gastric cancer. Cochrane Database Syst
Rev. CD0040642010.PubMed/NCBI
|
|
7
|
Wesolowski R, Lee C and Kim R: Is there a
role for second-line chemotherapy in advanced gastric cancer?
Lancet Oncol. 10:903–912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baek SK, Kim SY, Jeong JH, Cho KS and Yoon
HJ: Second-line chemotherapy for advanced gastric cancer in Korea.
Gastric Cancer. 15:345–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: To GA Trial Investigators: Trastuzumab in combination
with chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang YK, Kang WK, Shin DB, Chen J, Xiong
J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, PhilcoSalas
M, et al: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in patients with advanced gastric cancer: A
randomised phase III noninferiority trial. Ann Oncol. 20:666–673.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, Toh Y, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu
J and Ohtsu A: Gastrointestinal Oncology Study Group of the Japan
Clinical Oncology Group. Fluorouracil versus combination of
irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:
A randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Al-Batran SE, Hartmann JT, Probst S,
Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G,
Homann N, Wilhelm G, Schuch G, et al: Arbeitsgemeinschaft
Internistische Onkologie. Phase III trial in metastatic
gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus
either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft
Internistische Onkologie. J Clin Oncol. 26:1435–1442. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
VanCutsem E, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, Risse ML and Ajani JA: V325 study group. Phase III study of
docetaxel and cisplatin plus fluorouracil compared with cisplatin
and fluorouracil as first-line therapy for advanced gastric cancer:
A report of the V325 study group. J Clin Oncol. 24:4991–4997. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen XL, Chen XZ, Yang C, Liao YB, Li H,
Wang L, Yang K, Li K, Hu JK, Zhang B, Chen ZX, et al: Docetaxel,
cisplatin and fluorouracil (DCF) regimen compared with
non-taxane-containing palliative chemotherapy for gastric
carcinoma: A systematic review and meta-analysis. PLoS One.
8:e603202013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dank M, Zaluski J, Barone C, Valvere V,
Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K and Bugat
R: Randomized phase III study comparing irinotecan combined with
5-fluorouracil and folinic acid to cisplatin combined with
5-fluorouracil in chemotherapy naive patients with advanced
adenocarcinoma of the stomach or esophagogastric junction. Ann
Oncol. 19:1450–1457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moehler M, Kanzler S, Geissler M, Raedle
J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR and Hoehler
T: Arbeitsgemeinschaft Internistische Onkologie, Germany. A
randomized multicenter phase II study comparing capecitabine with
irinotecan or cisplatin in metastatic adenocarcinoma of the stomach
or esophagogastric junction. Ann Oncol. 21:71–77. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW,
Baek SK, Kim TY, Ryu MH, Nam BH and Zang DY: Second-line
chemotherapy versus supportive cancer treatment in advanced gastric
cancer: A meta-analysis. Ann Oncol. 24:2850–2854. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
ThussPatience PC, Kretzschmar A, Bichev D,
Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G
and Reichardt P: Survival advantage for irinotecan versus best
supportive care as second-line chemotherapy in gastric cancer - a
randomised phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang JH, Lee SI, Lim do H, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ford HE, Marshall A, Bridgewater JA,
Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S,
Middleton GW, Swinson D, et al: COUGAR-02 Investigators: Docetaxel
versus active symptom control for refractory oesophagogastric
adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised
controlled trial. Lancet Oncol. 15:78–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hironaka S, Ueda S, Yasui H, et al:
Randomized, open-label, phase III study comparing irinotecan with
paclitaxel in patients with advanced gastric cancer without severe
peritoneal metastasis after failure of prior combination
chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park JS, Lim JY, Park SK, Kim MK, Ko HS,
Yoon SO, Kim JW, Choi SH and Cho JY: Prognostic factors of second
and third line chemotherapy using 5-fu with platinum, irinotecan
and taxane for advanced gastric cancer. Cancer Res Treat.
43:236–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH
and Chung IJ: Prognostic factor analysis of third-line chemotherapy
in patients with advanced gastric cancer. Gastric Cancer.
14:249–256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee MJ, Hwang IG, Jang JS, Choi JH, Park
BB, Chang MH, Kim ST, Park SH, Kang MH and Kang JH: Outcomes of
third-line docetaxel-based chemotherapy in advanced gastric cancer
who failed previous oxaliplatin-based and irinotecan-based
chemotherapies. Cancer Res Treat. 44:235–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Webb A, Cunningham D, Scarffe JH, Harper
P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates
J, et al: Randomized trial comparing epirubicin, cisplatin, and
fluorouracil versus fluorouracil, doxorubicin and methotrexate in
advanced esophagogastric cancer. J Clin Oncol. 15:261–267. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao
JC, Abbruzzese JL, Ho L, Ajani J and Phan A: Weekly docetaxel,
cisplatin and 5-fluorouracil as initial therapy for patients with
advanced gastric and esophageal cancer. Cancer. 116:1446–1453.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Polyzos A, Felekouras E, Karatzas T,
Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D,
Karavokyros J, Nikiteas N, Tsavaris N, et al: Modified
docetaxel-cisplatin in combination with capecitabine as first-line
treatment in metastatic gastric cancer. A phase II study.
Anticancer Res. 32:4151–4156. 2012.PubMed/NCBI
|
|
30
|
Kanagavel D, Pokataev IA, Fedyanin MY,
Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM and
Tjulandin SA: A prognostic model in patients treated for metastatic
gastric cancer with second-line chemotherapy. Ann Oncol.
21:1779–1785. 2010. View Article : Google Scholar : PubMed/NCBI
|
